Delivery Order SPE2DB20D1109-SPE2DB25FP66E
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,071.19 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed price, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) valued at $6,223.32 on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled at the vendor's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $17,483.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit packaging) on July 14, 2025, with completion targeted for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. The order will be fulfilled...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $28,637.88 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-unit pack) on August 29, 2025, with completion targeted for September 2, 2025. This firm fixed-price contract, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a $32,046.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 22, 2025, with completion targeted for July 23, 2025. This non-competitive, non-set-aside delivery order represents a child contract action under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a delivery order valued at $48,759.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 6, 2025, with a completion date of August 7, 2025. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP66EDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, with extensive experience fulfilling diverse medication needs across multiple therapeutic domains for military and veteran healthcare systems. The company's role as a pharmaceutical prime vendor under the DLA framework reflects its capability to meet stringent federal procurement standards, particularly for specialty medications and controlled pharmaceutical products like RINVOQ (an oral JAK inhibitor used to treat conditions such as rheumatoid arthritis). This delivery order contributes to AmerisourceBergen's broader portfolio of federal medical supply contracts supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.7k | 8/28/25 |